Email alerts

Subscribe to our mailing list

Testimonials

Since Tri-Solfen® was commercially launched, over 80 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Close

Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
New
Zealand
Sheep,
Cattle
Granted
New
Zealand
Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
Cattle
Granted
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Cattle
Granted
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Pig
Granted
Canada Humans Granted

Close

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Close

Press Release

Prestigious grant to help fast-track new pain mitigation delivery via livestock feed supplements

September 24, 2018

New collaboration to advance animal wellbeing

Leader in animal wellbeing solutions, Medical Ethics Pty Ltd, and animal nutrition provider, 4 Season Company, have established a new collaboration to trial pain mitigation technologies via a unique feed supplement.

The research and development studies will involve incorporating a pain relief agent that is similar to human over-the-counter anti-inflammatory drugs, into a specially formulated feed supplement based on a unique molasses mineral block technology.

Bayer through its Care4Cattle initiative has awarded one of its three prestigious global grants to Dr. Dominique van der Saag and the Sydney University Veterinarian Science Faculty. The grant will assist Medical Ethics and 4 Season Company to commence the first stage of the proof of concept studies.

Medical Ethics and 4 Season Company are working together to develop the technology that has the potential to deliver a range of pain mitigation therapies for livestock undergoing routine surgical procedures such as castration, disbudding, and to assist in the recovery from other painful ailments such as hoof abscesses. The technology also has the potential to help reduce pain and stress to cows during calving.

Managing Director of Medical Ethics, Allan Giffard, commented:

“Whilst the technology is still in the early stages this announcement was one of the company’s most significant animal wellbeing initiatives since the commercialisation of the Tri-Solfen pain mitigation technology. The awarding of the prestigious Bayer grant to our research partners Sydney University indicates the enormous potential the technology has to improve animal wellbeing outcomes globally.

“Currently there are no products providing pain relief in a simple, accessible form for animals to self-medicate. The combination of the Tri-Solfen technology (protected by 35 patents globally) and the introduction of the pain mitigated infused feed supplement has the potential to provide a practical, cost efficient and highly effective pain mitigation combination.

“This latest initiative is an important addition to our growing research and development pipeline.”

Bayer Regulatory Affairs Manager and Animal Well-Being Lead, Cate McPherson commented:

“Bayer Australia is thrilled that Dr van der Saag has been awarded a Care4Cattle grant for this innovation in advancing the well-being of cattle. Coming in the wake of the recent approval of Tri-Solfen for the new claim in disbudding and dehorning in calves, this grant underlines Bayer’s commitment to support ethical and sustainable practices in Australia’s animal industries”

In May, Medical Ethics announced it was investing $5.3 million (AUD) in researching the use of its Tri-Solfen pain mitigation technology for treatment of wounds in humans. Since commercialisation, Tri-Solfen has treated over 80 million farm animals in Australia.

 

– Ends –

 

Contact:

Allan Giffard, Managing Director, Medical Ethics
0419 362 286

Celia Moore, FTI Consulting
0432 344 069

 

Notes for editors:

About Medical Ethics Pty Ltd
Medical Ethics Pty Ltd is a commercial and development company focused on pain mitigation in wounds for humans and animals. Our vision is to develop and deliver our proprietary highly effective, safe, affordable and practical pain relief platform to prevent pain and minimise suffering associated with wounds in humans, livestock and companion animals. Medical Ethics is focused on the development of the Group’s patented technology initially for the treatment of chronic wounds such as diabetic leg ulcers. Animal Ethics, a wholly owned subsidiary of Medical Ethics, is the first, and currently the only, company globally to develop, launch and commercialise a topical pain and wound management product for use in livestock undergoing painful husbandry procedures.

For further information, please visit http://medicalethics.me

About 4 Seasons Company
For further information, please visit https://www.fourseasonco.com.au/

Further information

Medical Ethics:

Allan Giffard, Managing Director
Charles Olsson, Marketing Director
+61 419 362 286

FTI Consulting:

Brett Pollard, Victoria Foster Mitchell
+44 (0)20 3727 1000